To accurately reflect the data presented in the main body of the text and current approved dosage recommendations for amlodipine, the final paragraph of the Pharmacokinetic Properties section of the summary on page 480 should read: In patients with hepatic cirrhosis amlodipine elimination is reduced and some degree of accumulation noted: elimination half-life is significantly prolonged and AUC increased. In the absence of approved dosage recommendations it would seem clinically prudent to initiate amlodipine at a low dosage and titrate to an adequate response, In the elderly there is also evidence that elimination half-life is prolonged and AUC increased, although this may simply reflect large intersubject variability and it would seem appropriate to start treatment with the lowest recommended amlodipine dosage. The pharmacokinetic profile of amlodipine does not appear to be significantly altered in patients with renal impairment, 856 1989, p. 197 Vol. 41, No.3, 1991: To accurately reflect the data presented in the main body of the text and current approved dosage recommendations for amlodipine, the final paragraph of the Pharmacokinetic Properties section of the summary on page 480 should read:
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